Skip to content
value.today

Vyome Holdings, Inc

HIND
$14 Mmarket cap on Oct 7, 2026
Compare
World rank
#25,174
Revenue
—
For year ending December-2025
Net income
$-10 M
SEC filing
Employees
18
As of December 31, 2025
SEC filing

Vyome Holdings, Inc in brief

Vyome Holdings, Inc is a listed company in the Biotechnology industry, based in San Clemente, California, USA. Its market value was $14 M on 7 October 2026, which makes it the 25,174th largest listed company in the world and the 4,223rd largest in the USA on this site. It employs about 18 people. Its largest product and service lines by sales in 2025 were Licensing and milestone fees – Luliconazole (37%) and Royalty income related to above product sales (9%). Its shares trade under the symbol HIND (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Vyome Holdings, Inc

On August 15, 2025, ReShape Lifesciences Inc. (now known as Vyome Holdings, Inc.) completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended, by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company, and Vyome Therapeutics, Inc.. Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company. As a result of the Merger, the Company was renamed “Vyome Holdings, Inc.” and Vyome continued under its name as Vyome Therapeutics, Inc., in each case effective before the open of trading on August 15, 2025.

From the company's annual report filed with the US SEC: read the report

Vyome Holdings, Inc timeline

5 events, 2008–2025
  1. 2008
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2016
  4. 🔔
    Initial public offering as Obalon Therapeutics Inc
    Final prospectus filed with the SEC on 6 October 2016; shares registered for exchange trading on 27 September 2016.
  5. 2021
  6. 💰
    Record revenue of $14 million
    FY2021, the highest of the 7 years on record.
  7. ✎
    Renamed ReShape Lifesciences Inc.
    Formerly Obalon Therapeutics Inc.
  8. 2025
  9. ✎
    Renamed Vyome Holdings, Inc
    Formerly ReShape Lifesciences Inc..

Events of Vyome Holdings, Inc from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.8×
Free cash flow yield
-117.6%
Net margin
—
Operating margin
—
Return on equity
-272.9%
Liabilities / assets
42.2%
Net debt
$10M
Revenue growth
-7.7%
R&D / revenue
3.6%
Profit per employee
$-570 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $9M, net income $-37M$9MFY18Fiscal year ending Dec 2019: revenue $3M, net income $-24M$3MFY19Fiscal year ending Dec 2020: revenue $11M, net income $-22M$11MFY20Fiscal year ending Dec 2021: revenue $14M, net income $-63M$14MFY21Fiscal year ending Dec 2022: revenue $11M, net income $-46M$11MFY22Fiscal year ending Dec 2023: revenue $9M, net income $-11M$9MFY23Fiscal year ending Dec 2024: revenue $8M, net income $-1M$8MFY24Fiscal year ending Dec 2025: revenue —, net income $-10M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-10M$-10M—
Dec 2024$8M-7.7%$-1M$-1M-18.1%
Dec 2023$9M-22.8%$-15M$-11M-131.2%
Dec 2022$11M-17.4%$-46M$-46M-411.1%
Dec 2021$14M+20.4%$-58M$-63M-464.3%
Dec 2020$11M+244.5%$-12M$-22M-191.4%
Dec 2019$3M-64.0%$-23M$-24M-722.0%
Dec 2018$9M—$-37M$-37M-410.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-4M——$-4.86—
Dec 2024$-1M——$-6001.39—
Dec 2023$-17M$0M$-17M$-110.87—
Dec 2022$-22M$0M$-22M$-108.90—
Dec 2021$-15M$0M$-16M$-288.97—
Dec 2020$-9M$0M$-9M$-5.54—
Dec 2019$-23M$0M$-23M$-5.03—
Dec 2018$-29M$1M$-31M$-19.64—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $2M, net income $3M$2MDec ’24Three months to Mar 2025: revenue $1M, net income $-0M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-0M$1MJun ’25Three months to Sep 2025: revenue $0M, net income $-8M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-1M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-1M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-1M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-1M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (+100.0% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Vyome Holdings, Inc with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-10 M
Net income
$-10 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$3 M
Total equity
$4 M

As of December-2025

Top 13 institutional investors in Vyome Holdings, Inc#

As of Sep 30, 2026
13 institutions held 120,200 shares (about 1.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 1.7%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 13 largest institutional investors in Vyome Holdings, Inc
#InstitutionShares heldChange (shares)% heldValueFiled
1Susquehanna International Group, LLP26,554+16,496 (+164.01%)0.38%$0 MNov 16, 2026
2Geode Capital Management, LLC25,580-213 (-0.83%)0.36%$0 MNov 6, 2026
3Vanguard Capital Management LLC14,927+5,464 (+57.74%)0.21%$0 MNov 13, 2026
4Focus Partners Wealth14,6400 (0.00%)0.21%$0 MNov 12, 2026
5HRT Financial LP13,834-6,484 (-31.91%)0.20%$0 MNov 13, 2026
6Vanguard Fiduciary Trust Co12,1950 (0.00%)0.17%$0 MNov 13, 2026
7Royal Bank Of Canada5,8560 (0.00%)0.08%$0 MNov 16, 2026
8UBS Group AG3,091-8,817 (-74.04%)0.04%$0 MNov 10, 2026
9Tower Research Capital LLC (TRC)2,516+708 (+39.16%)0.04%$0 MNov 16, 2026
10FMR LLC1,000New0.01%$0 MNov 10, 2026
11Caitong International Asset Management Co., Ltd30 (0.00%)0.00%$0 MOct 29, 2026
12Barclays PLC2-24 (-92.31%)0.00%$0 MNov 6, 2026
13Robinhood Markets, Inc.2—0.00%$0 MNov 18, 2026

Mutual funds holding Vyome Holdings, Inc#

3 funds hold shares worth $0 M (about 0.4% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Vyome Holdings, Inc
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC16,294$0 M0.23%<0.01%+13%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.9,463$0 M0.13%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC3,208$0 M0.05%<0.01%+87%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Vyome Holdings, Inc#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
37
since
-$12$0Nov 2023: bought $0 (0 trades), sold $9 (1 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $11 (1 trades)DecFeb 2024: bought $0 (0 trades), sold $7 (1 trades)FebMay 2024: bought $0 (0 trades), sold $12 (1 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Vyome Holdings, Inc: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mohanjit JollyDirectorGrant or awardindirect+454,456——454,456Form 4
filed Venkateswarlu NelabhotlaPresident and CEO, DirectorGrant or award+7——7Form 4
filed Robert Dickey IVChief Financial OfficerGrant or award+762——762Form 4
filed Thomas StankovichChief Financial OfficerSell-48$0.250$1222,777Form 4
filed Thomas StankovichChief Financial OfficerSell-43$0.170$722,825Form 4
filed Thomas StankovichChief Financial OfficerSell-42$0.250$1122,868Form 4
filed Thomas StankovichChief Financial OfficerSell-39$0.230$922,910Form 4
filed Thomas StankovichChief Financial OfficerSell-131$0.270$3522,949Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Vyome Holdings, Inc#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
18,468
0.3% of shares · 1.58 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split ; 1-for-58.14 reverse split ; 1-for-50 reverse split ; 1-for-3 reverse split ; 1-for-100 reverse split ; 1-for-2.9 reverse split ; 1-for-3 reverse split

Trading halts

  • 2026-01-27 15:09 UTC, code LUDP, resumed 15:14 UTC
  • 2026-01-27 14:58 UTC, code LUDP, resumed 15:08 UTC

Fails to deliver

  • : 2,226 shares at $2.06
  • : 2,649 shares at $1.91
  • : 1 shares at $1.93
  • : 5,920 shares at $1.99
  • : 2,338 shares at $2.04

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Vyome Holdings, Inc scorecard#

Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 7, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.9×Price to book 3.9× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-117.6%Free cash flow is -117.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.86 vs -6001.39Diluted EPS -4.86 in fiscal 2025 against -6001.39 the year before (report's currency).
    • ✓Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$22 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.99 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Vyome Holdings, Inc: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Vyome Holdings, Inc: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.38.08.7111411r3.39.19.93.4
Cost of revenue0.10.1r3.14.45.35.0r3.05.44.82.8
Gross profit0.20.2r5.56.88.36.3r0.33.75.10.6
Research and development0.60.3r2.32.52.4r3.5r6.911119.9
Selling, general and administrative2.40.97.5148.9r4.7r17302910
Selling and marketing—3.07.5———————
General and administrative—6.9101724r11————
Operating expenses111.2r215366r19r24413920
Operating income−10−1.0r−15−46−58r−12r−23−37−34−20
Interest expense and finance costs0.10.2————————
Other non-operating income (expense)−0.0−0.4r0.10.0—−0.4−0.1−0.2−0.2−0.0
Income before tax—−7.1−11−47−63r−22————
Income tax—0.00.1−0.4−0.3r−0.2r0.00.00.00.0
Net income including minority interests−10−1.4r−11−46−63r−22————
Minority interests' share of net income−0.2—————————
Net income attributable to shareholders−10−1.4r−11−46−63r−22r−24−37−35−20
Earnings per share, basic-4.86-6,001.39r-110.87r-108.90-288.97r-5.54r-5.03-19.64r-2.08-4.85
Earnings per share, diluted-4.86-6,001.39r-110.87r-108.90-288.97r-5.54r-5.03-19.64r-2.08-4.85
Shares, weighted average (basic)2.20.0r0.1r0.40.2r3.9————
Shares, weighted average (diluted)2.20.0r0.1r0.40.2r3.9r4.71.9r174.2
Balance sheet
Cash and cash equivalents5.00.1r4.53.9233.0r14212173
Short-term investments——————02.5232.5
Receivables0.00.0r1.7———0.30.94.20
Inventory—2.53.73.63.02.21.91.61.40.8
Other current assets0.10.1r0.10.10.20.2r2.02.51.71.2
Current assets5.40.3r109.930r8.9r18295278
Property, plant and equipment0.00.1r0.10.71.50.6r1.11.71.30.7
Right-of-use (leased) assets0.00.1r0.30.20.30.5r1.1———
Other intangible assets0.30.3—0.31413————
Non-current assets1.11.1————————
Total assets6.51.4r111153r37r20305379
Accounts payable0.60.5r1.71.93.53.7r0.61.21.30.6
Debt due within a year—0.8———3.609.92.00
Current liabilities2.75.7r3.87.57.5r12r4.017104.6
Long-term debt—————9.2r008.09.9
Lease liabilities (non-current)—0.0r0.2——0.2r0.6———
Non-current liabilities—0.0————0.60.08.09.9
Total liabilities2.75.8r4.07.58.2r23r4.5171814
Retained earnings−88−55r−636−624−578r−515r−172−149−111−77
Shareholders' equity—−4.4r6.73.744r14r24r133564
Minority interests1.30.0————————
Total equity3.8−4.4−6.2——4.716133564
Total liabilities and equity6.51.4r111153r37r20305379
Shares outstanding5.9—0.4r0.50.4r3.5r7.72.4r1817
Cash-flow statement
Depreciation and amortization0.00.0———0.30.5—0.30.2
Share-based compensation0.60.20.82.112r1.3r3.04.73.20.6
Cash from operating activities−3.7−0.6r−17−22−15−8.6r−23−29−31−19
Capital expenditure——−0.0−0.1−0.4−0.2−0.2−1.3−1.0−0.4
Acquisitions, net of cash acquired————−25—————
Cash from investing activities—0.0−0.0−0.11.9−2.4r2.420−226.2
Debt issued0.6————0.410000
Debt repaid————−110−200—0
Shares issued1.3—130.6—0239.80—
Cash from financing activities8.70.7r183.13311r1310.00.683
Exchange-rate effect on cash————0.0−0.1——00
Change in cash4.90.1r0.6−19200.0r−7.10.1−5270
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Vyome Holdings, Inc sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Sale of products(total)$0 M55%
  • Licensing and milestone fees – Luliconazole$0 M37%
  • Royalty income related to above product sales$0 M8.8%

Business segments

  • Pharmaceutical$0 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Vyome Holdings, Inc#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Delisting noticeFiling

Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 8 · Unregistered share sale 1 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 5 · Results announced 3

Vyome Holdings, Inc: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Auditor changedMaterial agreement8-K
Acquisition or sale completedDirectors and officersUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Shareholder vote8-K
Material agreement8-K
Material agreement8-K
Delisting notice8-K
Material agreement8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 28, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Vyome Holdings, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2018$10 MPrivate placement after listing$10 to $50 million21equitySEC
Aug 2014$16 MNo. 4$10 to $50 million5equitySEC
Dec 2012$5 MNo. 3$2 to $10 million1equitySEC
May 2012$17 MNo. 2$10 to $50 million3equitySEC
Feb 2012$2 MNo. 1Under $2 million2debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Vyome Holdings, Inc#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
49
2019–2019
Latest
49 people
2019-04-02
Vyome Holdings, Inc: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2019···49········49
Vyome Holdings, Inc: latest layoffs
AnnouncedPeopleKindWhereSource
49 people (50% of workforce)Restructuring planSEC 8-K“On April 2, 2019, the Company notified approximately 49 employees whose employment will be terminated, or approximately 50% of its workforce, with the intent to refocus activities,…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Vyome Holdings, Inc compares in Biotechnology

  • Market cap$14 M · higher than 14% of 726
  • Revenue growth-7.7% · higher than 35% of 438
  • Price / book3.9× · lower than 40% of 534
  • FCF yield-117.6% · higher than 9% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Vyome Holdings, Inc🇺🇸$14 M——-7.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 7, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Vyome Holdings, Inc? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Vyome Holdings, Inc's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Vyome Holdings, Inc? Suggest a correction